Related Experiment Video
Updated: Dec 26, 2025

A Treatment Package without Escape Extinction to Address Food Selectivity
Published on: August 21, 2015
Successful desensitization of Pegvaliase (Palynziq®) in a patient with phenylketonuria
Meera Patrawala1,2, Merin Kuruvilla1,2, Hong Li3,2
1Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, Emory University, Atlanta, GA, United States of America.
Abstract:
Pegvaliase (Palynziq®) was FDA approved in 2018 as an enzyme substitution therapy in patients with Phenylketonuria. However, various drug induced hypersensitivity adverse events (HAEs) have been reported. We present a case of Pegvaliase (Palynziq®) induced anaphylaxis and successful desensitization. A 13-step desensitization protocol was performed using three solution concentrations of Palynziq with premedication of diphenhydramine and prednisone in an outpatient setting. The patient tolerated the desensitization and was able to continue Palynziq.
Related Concept Videos
Inborn Errors of Metabolism
Desensitization and Tachyphylaxis
GPCR Desensitization
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
A study on guinea pigs examined the...
Insensitive Nuclei Enhanced by Polarization Transfer (INEPT)

